ARTICLE | Company News
Endovasc, Stanford University deal
July 7, 2003 7:00 AM UTC
The university received a $300,000 milestone from ENDV under a 2002 deal (see BioCentury, Feb. 11, 2002). ENDV's proposed filing of an IND application for a Phase III trial of Angiogenix to treat chro...